OCT 01, 2015 12:00 PM PDT

Keynote Presentation (during an actual infusion!): Patient #1 - Pioneering Immunotherapy and Finding The Best, Right Treatment for Stage IV Melanoma

Speakers
  • Patient, Survivor, Advocate, and Author of the "Patient #1" blog
    Biography
      T.J. Sharpe is sharing his fight against Stage 4 Melanoma in his weekly Patient #1 blog on www.Philly.com/Patient1. A South Jersey native and Bishop Eustace and Carnegie Mellon University graduate, he currently lives in Fort Lauderdale, FL with his wife Jennifer and children Josie and Tommy. He was Patient #1 in a clinical trial at Moffitt Cancer Center in Tampa as the first person worldwide to use this sequence of treatments to fight melanoma, and is currently in a second clinical trial at Holy Cross Hospital in Fort Lauderdale receiving Merck's anti-PD-1 drug pembrolizumab

    Abstract:

    Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turned into a metastatic melanoma diagnosis. His quest to overcome these long odds and beat cancer has taken him through two clinical trials, four immunotherapies, and six surgeries – all while sharing the highs and lows of cancer treatment on www.Philly.com. Fortunately, those three years have seen a great advance in melanoma treatments, one Mr. Sharpe has witnessed first-hand and shared with the world through his blog, advocacy speaking, and participation in conferences for cancer, biotechnology, and clinical trials. Being a husband and father (second child Tommy was born a mere four weeks before the diagnosis), his story combines the medicinal side of the current immunotherapy treatments being presented at the Labroots Cancer Research and Oncology event, alongside how these treatments affect everyday life. It also gives medical professionals, researchers, caretakers, and other cancer patients insight into getting the best, right care and how to overcome the avalanche of information and decisions that a cancer diagnosis brings. While he is sharing his patient perspective, T.J. will receive his 42nd dose of pembrolizumab, as part of the second clinical trial.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    AUG 15, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 15, 2019 09:00 AM PDT
    DATE: August 15, 2019TIME: 9:00am PDT, 12:00pm EDT Radiation therapy is a critical tool for the treatment of brain tumors, however, exposure to high doses of ionizing radiation...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    JUL 31, 2019 09:00 AM PDT
    C.E. CREDITS
    JUL 31, 2019 09:00 AM PDT
    DATE: July 31, 2019TIME: 9:00am PT, 12:00pm ET The choroid plexus, which makes up the blood-cerebrospinal fluid barrier in the central nervous system (CNS), lines the ventricle...
    Loading Comments...
    Show Resources